Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 435 participants.
Also called NCT01693029
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 435 participants
- Sponsor
- Sandoz
- Registry
-
NCT01693029
-
- Other papers using this trial's data
- A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01693029. Randomized; quadruple masking; primary purpose treatment. Start 2012-09 (registry gives no type); primary completion 2014-05 (actual). Results posted on 2017-05-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
- Acronym
- ACCESS
- Condition
- Anemia
- Intervention (Drug)
- HX575 epoetin alfa
- Intervention (Drug)
- US-licensed epoetin alfa
- Lead sponsor
- Sandoz
Record details
- Record id
cardio:ct-nct01693029- Content hash
7c455b6145ec4809620c32d02fd43d0e8873f72a862d4393297e50f0f4dca105